Drug intelligence / Profile preview

BB-IO

Development stage: Preclinical
Lead developer: BroadenBio
Administration: Intraosseous

Overview

BB-IO is a preclinical-stage drug candidate developed by BrodenBio, a biotechnology company specializing in oncology therapeutics. Positioned within the company's immuno-oncology (IO) pipeline, BB-IO is being investigated for the treatment of "tumor infection," an indication that likely involves the modulation of the immune response within the tumor microenvironment or potentially an oncolytic approach. As of early 2024, specific details regarding its molecular target, modality (such as small molecule or biologic), and precise mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on BB-IO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-IO.

Explore the full profile